# Oxycodone/naloxone

> Mediated Wiki article. Canonical URL: https://mediated.wiki/source/Oxycodone/naloxone
> Markdown URL: https://mediated.wiki/source/Oxycodone/naloxone.md
> Source: https://en.wikipedia.org/wiki/Oxycodone%2Fnaloxone
> Source revision: 1317097470
> License: Creative Commons Attribution-ShareAlike 4.0 International (https://creativecommons.org/licenses/by-sa/4.0/)

**Oxycodone/naloxone**, sold under the brand name **Targin** among others, is a combination [pain medication](/source/Pain_medication) available as [modified-release](/source/Modified-release) tablets administered [by mouth](/source/By_mouth).[5]

The [oxycodone](/source/Oxycodone) component is an [opioid](/source/Opioid) and is responsible for the pain-relieving effects. [Naloxone](/source/Naloxone), an [opioid antagonist](/source/Opioid_antagonist), opposes the effects of opioids but is poorly absorbed into the blood stream when administered orally; therefore, most of the dose remains in the [gastrointestinal tract](/source/Gastrointestinal_tract). This local presence reduces opioid-induced [constipation](/source/Constipation) by preventing oxycodone from binding to gut opioid receptors, without diminishing overall analgesic efficacy compared to oxycodone alone. A 2008 study demonstrated a significant reduction in constipation.[6] Oxycodone/naloxone was released in 2014 in the United States,[5] in 2006 in Germany, and has been available in some other European countries since 2009. In the United Kingdom, the 10 mg oxycodone / 5 mg naloxone and 20 mg / 10 mg strengths were approved in December 2008, and the 40 mg / 20 mg and 5 mg / 10 mg strengths received approval in July 2019.[7]

Preliminary evidence suggests that oxycodone/naloxone may be an effective treatment for severe, refractory [restless legs syndrome](/source/Restless_legs_syndrome) if first-line therapies have not been effective.[8][9][10]

## Adverse effects

Further information: [Oxycodone#Adverse effects](/source/Oxycodone#Adverse_effects)

## References

1. ["Public Summary"](http://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=355284&agid=%28PrintDetailsPublic%29&actionid=1). *www.ebs.tga.gov.au*. Australian Government, Department of Health and Aged Care. Retrieved 2024-05-20.

1. ["Oxonal (AU Pharma Pty Ltd)"](https://www.tga.gov.au/resources/prescription-medicines-registrations/oxonal-au-pharma-pty-ltd). *Therapeutic Goods Administration (TGA)*. 28 September 2022. [Archived](https://web.archive.org/web/20230318070824/https://www.tga.gov.au/resources/prescription-medicines-registrations/oxonal-au-pharma-pty-ltd) 18 March 2023 at the Wayback Machine. Retrieved 9 April 2023.

1. ["Targin Product information"](https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82520). *Health Canada*. 22 October 2009. [Archived](https://web.archive.org/web/20230429044124/https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82520) 29 April 2023 at the Wayback Machine. Retrieved 9 April 2023.

1. ["Targinact 5 mg/2.5 mg prolonged-release tablets - Summary of Product Characteristics (SmPC)"](https://www.medicines.org.uk/emc/product/503/smpc). *(emc)*. 16 March 2021. [Archived](https://web.archive.org/web/20230410055627/https://www.medicines.org.uk/emc/product/503/smpc) 10 April 2023 at the Wayback Machine. Retrieved 9 April 2023.

1. ["Targiniq ER- oxycodone hydrochloride/naloxone hydrochloride tablet, film coated, extended release"](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=98e70c9c-fa3c-e63f-41d4-dac3c6fec51d). *DailyMed*. 22 December 2016. [Archived](https://web.archive.org/web/20230318070843/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=98e70c9c-fa3c-e63f-41d4-dac3c6fec51d) 18 March 2023 at the Wayback Machine. Retrieved 18 March 2023.

1. Simpson K, Leyendecker P, Hopp M, Müller-Lissner S, Löwenstein O, De Andrés J, Troy Ferrarons J, Bosse B, Krain B, Nichols T, Kremers W, Reimer K (December 2008). ["Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain"](http://www.informapharmascience.com/doi/abs/10.1185/03007990802584454). *Current Medical Research and Opinion*. **24** (12): 3503–3512. [doi:10.1185/03007990802584454](https://doi.org/10.1185/03007990802584454). [PMID 19032132](https://pubmed.ncbi.nlm.nih.gov/19032132). [S2CID 73061000](https://api.semanticscholar.org/CorpusID:73061000). [Archived](https://archive.today/20130126165345/http://www.informapharmascience.com/doi/abs/10.1185/03007990802584454) 2013-01-26 at the Wayback Machine. Retrieved 2009-04-09.

1. Mundipharma (2009-01-26). ["Targin (oral oxycodone/naloxone prolonged-release tablet) now launching across Europe to control severe chronic pain with significantly reduced risk of opioid-induced constipation"](http://www.prnewswire.com/mnr/targin/36704/). [Archived](https://web.archive.org/web/20090317092117/http://www.prnewswire.com/mnr/targin/36704/) 2009-03-17 at the Wayback Machine. Retrieved 2009-04-09.

1. de Biase S, Valente M, Gigli GL (2016). "Intractable restless legs syndrome: role of prolonged-release oxycodone-naloxone". *Neuropsychiatric Disease and Treatment*. **12**: 417–425. [doi:10.2147/NDT.S81186](https://doi.org/10.2147/NDT.S81186). [PMC 4770072](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770072). [PMID 26966363](https://pubmed.ncbi.nlm.nih.gov/26966363)

1. Trenkwalder C, Beneš H, Grote L, García-Borreguero D, Högl B, Hopp M, Bosse B, Oksche A, Reimer K, Winkelmann J, Allen RP, Kohnen R (December 2013). "Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension". *The Lancet. Neurology*. **12** (12): 1141–1150. [doi:10.1016/S1474-4422(13)70239-4](https://doi.org/10.1016/S1474-4422(13)70239-4). [PMID 24140442](https://pubmed.ncbi.nlm.nih.gov/24140442). [S2CID 35122538](https://api.semanticscholar.org/CorpusID:35122538)

1. de Oliveira CO, Carvalho LB, Carlos K, Conti C, de Oliveira MM, Prado LB, Prado GF (June 2016). "Opioids for restless legs syndrome". *The Cochrane Database of Systematic Reviews*. **2016** (6). [doi:10.1002/14651858.CD006941.pub2](https://doi.org/10.1002/14651858.CD006941.pub2). [PMC 6885031](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885031). [PMID 27355187](https://pubmed.ncbi.nlm.nih.gov/27355187)

---
Adapted from the Wikipedia article [Oxycodone/naloxone](https://en.wikipedia.org/wiki/Oxycodone%2Fnaloxone) by Wikipedia contributors ([contributor history](https://en.wikipedia.org/wiki/Oxycodone%2Fnaloxone?action=history)). Available under [Creative Commons Attribution-ShareAlike 4.0 International](https://creativecommons.org/licenses/by-sa/4.0/). Changes may have been made.